Literature DB >> 23997067

Severe interstitial lung disease following treatment with certolizumab pegol: a case report.

Jakob Lager, Ole Hilberg, Anders Løkke, Elisabeth Bendstrup.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23997067     DOI: 10.1183/09059180.00002013

Source DB:  PubMed          Journal:  Eur Respir Rev        ISSN: 0905-9180


× No keyword cloud information.
  5 in total

Review 1.  Treatment of rheumatoid arthritis-associated interstitial lung disease: a perspective review.

Authors:  Kundan Iqbal; Clive Kelly
Journal:  Ther Adv Musculoskelet Dis       Date:  2015-12       Impact factor: 5.346

Review 2.  Consensus recommendations on managing the selected comorbidities including cardiovascular disease, osteoporosis, and interstitial lung disease in rheumatoid arthritis.

Authors:  Kuang-Hui Yu; Hsin-Hua Chen; Tien-Tsai Cheng; Yeong-Jian Jan; Meng-Yu Weng; Yeong-Jang Lin; Hung-An Chen; Jui-Tseng Cheng; Kuang-Yung Huang; Ko-Jen Li; Yu-Jih Su; Pui-Ying Leong; Wen-Chan Tsai; Joung-Liang Lan; Der-Yuan Chen
Journal:  Medicine (Baltimore)       Date:  2022-01-07       Impact factor: 1.889

Review 3.  The safety of biologic therapies in RA-associated interstitial lung disease.

Authors:  Meghna Jani; Nik Hirani; Eric L Matteson; William G Dixon
Journal:  Nat Rev Rheumatol       Date:  2013-12-24       Impact factor: 20.543

Review 4.  Management of Rheumatoid Arthritis Patients with Interstitial Lung Disease: Safety of Biological Antirheumatic Drugs and Assessment of Pulmonary Fibrosis.

Authors:  Shunsuke Mori
Journal:  Clin Med Insights Circ Respir Pulm Med       Date:  2015-09-08

Review 5.  Treatment of Rheumatoid Arthritis-Associated Interstitial Lung Disease: Lights and Shadows.

Authors:  Giulia Cassone; Andreina Manfredi; Caterina Vacchi; Fabrizio Luppi; Francesca Coppi; Carlo Salvarani; Marco Sebastiani
Journal:  J Clin Med       Date:  2020-04-10       Impact factor: 4.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.